Trial Profile
A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of High-Dose Valacyclovir Versus Once Daily Valacyclovir on Herpes Simplex Virus Type 2 Genital Shedding in Herpes Simplex Virus-2 Seropositive Adults
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Valaciclovir (Primary)
- Indications Herpes genitalis; Herpes simplex virus type 2 infections
- Focus Therapeutic Use
- 05 Jan 2012 Results published ahead of print in the lancet.
- 05 Jan 2012 Status changed from active, no longer recruiting to completed, results have been published.
- 06 May 2011 New trial record